The opening of Canada’s recreational marijuana market in October is undeniably big, but the validation of marijuana as medicine could be even more important.
In this clip from The Motley Fool’s Industry Focus: Healthcare, analyst Shannon Jones and Todd Campbell discuss why FDA approval of GW Pharmaceuticals (NASDAQ: GWPH) cannabis-derived epilepsy drug was must-know news this year.
Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: